James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 7,909 shares at $14.52 ($115K) on 2026-03-02, disclosed to the SEC on 2026-03-04.
Seasonal sale ($115k) by Chief Financial Officer — this insider has traded AMLX in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |
| AMLX | SELL | 2025-04-02 | $38K | — | Filing → |